Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of High-Dose Galantamine in Alzheimer's Disease
NCT00338117Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Aug 1995
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
01
Overview
A Phase 3 trial of galantamine in Alzheimer's disease (AD), sponsored by Johnson & Johnson. Started Aug 1995; status: completed.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00338117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00338117.